European cancer mortality predictions for the year 2014, Annals of Oncology, vol.25, issue.8, pp.1650-1656, 2014. ,
DOI : 10.1093/annonc/mdu138
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.56-68, 2015. ,
DOI : 10.1093/annonc/mdv295
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011. ,
DOI : 10.1056/NEJMoa1011923
URL : https://hal.archives-ouvertes.fr/hal-00598658
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial, Journal of Clinical Oncology, vol.31, issue.1, pp.23-32, 2013. ,
DOI : 10.1200/JCO.2012.44.4869
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology, Quality of Life Research, vol.8, issue.1, pp.1713-1736, 2016. ,
DOI : 10.1586/14737167.8.2.179
When is Cancer Care Cost-Effective? A Systematic Overview of Cost???Utility Analyses in Oncology, JNCI: Journal of the National Cancer Institute, vol.102, issue.2, pp.82-90, 2010. ,
DOI : 10.1093/jnci/djp472
The Cloudy Crystal Ball of Cost-Effectiveness Studies, Value in Health, vol.16, issue.6, pp.1100-1102, 2013. ,
DOI : 10.1016/j.jval.2013.06.012
Methods for the economic evaluation of health care programmes, 2015. ,
Quality assessment of economic evaluation studies in pediatric surgery: A systematic review, Journal of Pediatric Surgery, vol.50, issue.4, pp.659-87, 2015. ,
DOI : 10.1016/j.jpedsurg.2015.01.012
Choices in methods for economic evaluation. Public Health Assessment Haute Autorité de Santé, 2012. ,
Health outcomes in economic evaluation: the QALY and utilities, British Medical Bulletin, vol.96, issue.1, pp.5-21, 2010. ,
DOI : 10.1093/bmb/ldq033
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)???Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force, Value in Health, vol.16, issue.2, pp.231-50, 2013. ,
DOI : 10.1016/j.jval.2013.02.002
Economic Analysis in Randomized Control Trials, Medical Care, vol.30, issue.3, pp.231-274, 1992. ,
DOI : 10.1097/00005650-199203000-00005
Guidelines for authors and peer reviewers of economic submissions to the BMJ, BMJ, vol.313, issue.7052, pp.275-83, 1996. ,
DOI : 10.1136/bmj.313.7052.275
Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996, The Journal of Mental Health Policy and Economics, vol.276, issue.2, pp.91-93, 1996. ,
DOI : 10.1001/jama.1996.03540160061034
Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria, Int J Technol Assess Health Care, vol.21, pp.240-245, 2005. ,
Developing a scoring system to quality assess economic evaluations, The European Journal of Health Economics, vol.3, issue.2, pp.131-137, 2002. ,
DOI : 10.1007/s10198-002-0100-2
Cost analysis of pancreatic carcinoma treatment, Cancer, vol.89, issue.9, 2000. ,
DOI : 10.1002/1097-0142(20001101)89:9<1917::AID-CNCR7>3.0.CO;2-L
Costs and trends in pancreatic cancer treatment, Cancer, vol.105, issue.8 suppl, pp.5132-5141, 2012. ,
DOI : 10.1038/ajg.2010.32
Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement, Annals of Surgical Oncology, vol.29, issue.12, pp.3659-67, 2012. ,
DOI : 10.1200/JCO.2010.32.1075
The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma, Annals of Surgical Oncology, vol.204, issue.S3, pp.500-508, 2013. ,
DOI : 10.1016/j.jamcollsurg.2006.12.011
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK, The European Journal of Health Economics, vol.4, issue.3, pp.216-237, 2003. ,
DOI : 10.1007/s10198-003-0173-6
Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer, Current Oncology, vol.21, issue.1, pp.41-51, 2014. ,
DOI : 10.3747/co.21.1327
Costeffectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study, Med Oncol, p.32, 2015. ,
-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study, Expert Review of Pharmacoeconomics & Outcomes Research, vol.16, issue.4, pp.579-89, 2015. ,
DOI : 10.1586/erp.13.18
URL : https://hal.archives-ouvertes.fr/halshs-00741378
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer, British Journal of Cancer, vol.15, issue.8, pp.1301-1306, 2015. ,
DOI : 10.1200/JCO.2011.36.5742
Cost-effectiveness of systemic therapies for metastatic pancreatic cancer, Curr Oncol, vol.201320 ,
Pancreatic cancer ??? cost for overtreatment with gemcitabine, Acta Oncologica, vol.30, issue.6, pp.1146-51, 2013. ,
DOI : 10.1158/1078-0432.CCR-09-1555
Pancreaticoduodenectomy with Vascular Resection for Local Advanced Pancreatic Head Cancer: A Single Center Retrospective Study, Journal of Gastrointestinal Surgery, vol.21, issue.12, pp.2183-90, 2008. ,
DOI : 10.1136/gut.2006.113068
An analysis of cost and clinical outcome in palliation for advanced pancreatic cancer, The American Journal of Surgery, vol.190, issue.3, pp.406-417, 2005. ,
DOI : 10.1016/j.amjsurg.2005.03.014
Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer, International Journal of Radiation Oncology*Biology*Physics, vol.67, issue.1, pp.211-219, 2007. ,
DOI : 10.1016/j.ijrobp.2006.07.1390
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer, Cancer, vol.82, issue.3 suppl, pp.1119-1148, 2012. ,
DOI : 10.1054/bjoc.2000.1142
The clinical and economic impact of alternative staging strategies for adenocarcinoma of the pancreas, The American Journal of Gastroenterology, vol.45, issue.7, pp.1708-1721, 2000. ,
DOI : 10.1146/annurev.med.46.1.361
A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma, The American Journal of Gastroenterology, vol.117, issue.9 ,
DOI : 10.1016/S0002-9610(97)00132-3
Pancreatic cancer: cost-effectiveness of imaging technologies for assessing resectability A costminimization analysis of alternative strategies in diagnosing pancreatic cancer, Radiology Am J Gastroenterol, vol.22199, pp.2223-2257, 2001. ,
Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness, Annals of Surgery, vol.242, issue.2, pp.235-278, 2005. ,
DOI : 10.1097/01.sla.0000172095.97787.84
Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?, Journal of Gastrointestinal Surgery, vol.153, issue.9, pp.1177-84, 2008. ,
DOI : 10.1001/archpedi.153.9.965
Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?, HPB, vol.13, issue.10, pp.732-739, 2011. ,
DOI : 10.1111/j.1477-2574.2011.00366.x
Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument, HPB, vol.17, issue.2, pp.131-140, 2015. ,
DOI : 10.1111/hpb.12325
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds, Gastrointestinal Endoscopy, vol.57, issue.1, pp.23-32, 2003. ,
DOI : 10.1067/mge.2003.28
Peutz???Jeghers syndrome and screening for pancreatic cancer, British Journal of Surgery, vol.15, issue.12, pp.1446-55, 2006. ,
DOI : 10.4161/cbt.183
A Clinical and Economic Evaluation of Endoscopic Ultrasound for Patients at Risk for Familial Pancreatic Adenocarcinoma, Pancreatology, vol.7, issue.5-6, pp.514-539, 2007. ,
DOI : 10.1159/000108969
Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature, International Journal of Cancer, vol.9, issue.10, pp.2392-2399, 2013. ,
DOI : 10.1159/000210262
Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis, The American Journal of Gastroenterology, vol.200, issue.4, pp.898-904, 2002. ,
DOI : 10.1111/j.1572-0241.2001.03594.x
Expandable Metal Biliary Stents Before Pancreaticoduodenectomy for Pancreatic Cancer: A Monte-Carlo Decision Analysis, Clinical Gastroenterology and Hepatology, vol.3, issue.12, pp.1229-1266, 2005. ,
DOI : 10.1016/S1542-3565(05)00886-4
Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis, Endoscopy, vol.39, issue.04, pp.319-343, 2007. ,
DOI : 10.1055/s-2007-966263
Is It Worth Looking? Abdominal Imaging After Pancreatic Cancer Resection: a National Study, Journal of Gastrointestinal Surgery, vol.116, issue.7, pp.121-129, 2012. ,
DOI : 10.1002/cncr.24918
Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis, Annals of Surgical Oncology, vol.3, issue.7, pp.2197-203, 2013. ,
DOI : 10.1245/ASO.2004.03.040
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews, BMC Medical Research Methodology, vol.333, issue.4, p.10, 2007. ,
DOI : 10.1136/bmj.333.7568.597
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews, Journal of Clinical Epidemiology, vol.62, issue.10, pp.1013-1033, 2009. ,
DOI : 10.1016/j.jclinepi.2008.10.009
Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review, PharmacoEconomics, vol.12, issue.1, pp.83-95, 2017. ,
DOI : JOP.2015.005876
Comparison of three instruments assessing the quality of economic evaluations: A practical exercise on economic evaluations of the surgical treatment of obesity, International Journal of Technology Assessment in Health Care, vol.29, issue.03, pp.318-343, 2008. ,
DOI : 10.1037/0033-2909.86.2.420
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance, PharmacoEconomics, vol.121, issue.2, pp.47-61, 2014. ,
DOI : 10.1007/s10549-010-0870-7
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6, Value in Health, vol.15, issue.6, pp.835-877, 2012. ,
DOI : 10.1016/j.jval.2012.04.014
The Quality of Reporting in Published Cost-Utility Analyses, 1976???1997, Annals of Internal Medicine, vol.132, issue.12, pp.964-72, 2000. ,
DOI : 10.7326/0003-4819-132-12-200006200-00007
Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?, Journal of Clinical Pharmacy and Therapeutics, vol.3, issue.2, pp.189-97, 2016. ,
DOI : 10.1007/s11912-001-0027-2
Cost???utility analyses of drug therapies in breast cancer: a systematic review, Breast Cancer Research and Treatment, vol.26, issue.Suppl 5 Develop, pp.407-431, 2016. ,
DOI : 10.2165/00019053-200826050-00005